The T cell antigen receptor: The Swiss army knife of the immune system

Clinical and Experimental Immunology

Volumn 181, Issue 1, 2015, Pages 1-18

  Attaf, M ^a   Legut, M ^a   Cole, D K ^a   Sewell, A K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

CD1; MHC I; MHC Ib; MHC II; MR1; T cell; T cell receptor; TCR; TCR

Indexed keywords

LIPID; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; BUTYROPHILIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MEMBRANE PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; BIODIVERSITY; CELL LINEAGE; CROSS REACTION; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THYMUS; IMMUNOLOGY;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 84930416677     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12622     Document Type: Article

References (122)

1. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248:701-2.
2. Treiner E, Duban L, Bahram S et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 2003; 422:164-9.
3. Le Bourhis L, Martin E, Peguillet I et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010; 11:701-8.
4. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 1994; 372:691-4.
5. Van Rhijn I, Kasmar A, de Jong A et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat Immunol 2014; 14:706-13.
6. Carding SR, Egan PJ. γδ T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002; 2:336-45.
7. Pellicci DG, Uldrich AP, Le Nours J et al. The molecular bases of δ/αβ T cell-mediated antigen recognition. J Exp Med 2014; 211:2599-615.
8. Allam A, Kabelitz D. TCR trans-rearrangements: biological significance in antigen recognition vs the role as lymphoma biomarker. J Immunol 2006; 176:5707-12.
9. Bowen S, Sun P, Livak F, Sharrow S, Hodes RJ. A novel T cell subset with trans-rearranged Vγ-Cβ TCRs shows Vβ expression is dispensable for lineage choice and MHC restriction. J Immunol 2014; 192:169-77.
10. Cole DK, Yuan F, Rizkallah PJ et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009; 284:27281-9.
11. Allison TJ, Winter CC, Fournié JJ, Bonneville M, Garboczi DN. Structure of a human gammadelta T-cell antigen receptor. Nature 2001; 411:820-4.
12. Gras S, Chen Z, Miles JJ et al. Allelic polymorphism in the T cell receptor and its impact on immune responses. J Exp Med 2010; 207:1555-67.
13. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol 2012; 2:669-77.
14. Davis MM, Bjorkmann PJ. T cell antigen receptor genes and T cell recognition. Nature 1988; 334:395-402.
15. Van Boehmer H, Teh HS, Kisielow P. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol Today 1989; 10:57-61.
16. Bendelac A. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 182:2091-6.
17. Coles MC, Raulet DH. NK1.1+ T cells in the liver arise in the thymus and are selected by interactions with class I molecules on CD4+CD8+ cells. J Immunol 2000; 164:2412-8.
18. Wei DG, Lee H, Park HS et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J Exp Med 2005; 202:239-48.
19. Seach N, Guerri L, Le Bourhis L et al. Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol 2013; 191:6002-9.
20. Wilson A, de Villartay JP, MacDonal HR. T cell receptor δ gene rearrangement and T early α (TEA) expression in immature αβ lineage thymocytes: implications for αβ/γδ lineage commitment. Immunity 1996; 4:37-45.
21. Coffey F, Lee SY, Buus TB et al. The TCR ligand-inducible expression of CD73 marks γδ lineage commitment and a metastable intermediate in effector specification. J Exp Med 2014; 211:329-43.
22. Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mechanism for the development of interferon-γ-secreting versus interleukin-17-secreting γδ T cells. Immunity 2011; 35:59-68.
23. Jensen KD, Su X, Shin S et al. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity 2008; 29:90-100.
24. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015; 43:D423-31.
25. Tynan FE, Borg NA, Miles JJ et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280:23900-9.
26. Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell 2002; 9:375-85.
27. Ekeruche-Makinde J, Miles JJ, van den Berg HA et al. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood 2013; 121:1112-23.
28. Probst-Kepper M, Hecht HJ, Herrmann H et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. J Immunol 2004; 173:5610-6.
29. Miles JJ, Borg NA, Brennan RM et al. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. J Immunol 2006; 177:6804-14.
30. Wynn KK, Fulton Z, Cooper L et al. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 2008; 111:4283-92.
31. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI. An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 1996; 4:203-13.
32. Sliz P, Michielin O, Cerottini JC et al. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 2001; 167:3276-84.
33. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993; 75:693-708.
34. Siebold C, Hansen BE, Wyer JR et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 2004; 101:1999-2004.
35. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7:473-81.
36. Deng L, Langley RJ, Brown PH et al. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol 2007; 8:398-408.
37. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24:419-66.
38. Hughes AL, Ota T, Nei M. Positive Darwinian selection promotes charge profile diversity in the antigen-binding cleft of class I major-histocompatibility-complex molecules. Mol Biol Evol 1990; 7:515-24.
39. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol 2014; 33:169-200.
40. Miles JJ, Bulek AM, Cole DK et al. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLOS Pathog 2010; 6:e1001198.
41. Yin Y, Li Y, Kerzic MC, Martin R, Mariuzza RA. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J 2011; 30:1137-48.
42. Merkenschlager M, Graf D, Lovatt M, Bommhardt U, Zamoyska R, Fisher AG. How many thymocytes audition for selection? J Exp Med 1997; 186:1149-58.
43. Scott-Browne JP, Crawford E, Young MH, Kappler JW, Marrack P, Gapin L. Evolutionarily conserved features contribute to αβ T cell receptor specificity. Immunity 2011; 35:526-35.
44. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009; 10:143.
45. Garcia KC. Reconciling views on T cell receptor germline bias for MHC. Trends Immunol 2012; 33:429-36.
46. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat Immunol 2007; 8:975-83.
47. Stadinski BD, Trenh P, Smith RL et al. A role for differential variable gene pairing in creating T cell receptors specific for unique major histocompatibility ligands. Immunity 2011; 35:694-704.
48. Burrows SR, Chen Z, Archbold JK et al. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proc Natl Acad Sci USA 2010; 107:10608-13.
49. Holland SJ, Bartok I, Attaf M et al. The T-cell receptor is not hardwired to engage MHC ligands. Proc Natl Acad Sci USA 2012; 109:E3111-8.
50. Yin Y, Wang XX, Mariuzza RA. Crystal structure of a complete ternary complex of T-cell receptor, peptide-MHC. Proc Natl Acad Sci USA 2012; 109:5405-10.
51. Cole DK, Miles KM, Madura Fet al. T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem 2013; 289:628-38.
52. Gao GF, Tormo J, Gerth UC et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature 1997; 387:630-4.
53. Van Laethem F, Sarafova SD, Park JH et al. Deletion of CD4 and CD8 coreceptors permits generation of αβT cells that recognize antigens independently of the MHC. Immunity 2007; 27:735-50.
54. Tikhonova AN, Van Laethem F, Hanada K et al. αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity 2012; 36:79-91.
55. Van Laethem F, Tikhonova AN, Singer A. MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection. Trends Immunol 2012; 33:437-41.
56. Van Laethem F, Tikhonova AN, Pobezinsky LA et al. Lck availability during thymic selection determines the recognition specificity of the T cell repertoire. Cell 2013; 154:1326-41.
57. Rao A, Ko WW, Faas SJ, Cantor H. Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T-cell clones. Cell 1984; 36:879-88.
58. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86:7159-63.
59. Hanada K, Wang QJ, Inozume T, Yang JC. Molecular identification of an MHC-independent ligand recognized by a human α/β T-cell receptor. Blood 2011; 117:4816-25.
60. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19:395-404.
61. Wooldridge L, Ekeruche-Makinde J, van den Berg HA et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 2012; 287:1168-77.
62. Bulek AM, Cole DK, Skowera A et al. Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes. Nat Immunol 2012; 13:283-9.
63. Birnbaum ME, Mendoza JL, Sethi DK et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014; 157:1073-87.
64. Madura F, Rizkallah PJ, Holland CJ et al. Structural basis for ineffective T-cell responses to MHC anchor residue-improved 'heteroclitic' peptides. Eur J Immunol 2015; 45:584-91.
65. Cole DK, Edwards ES, Wynn KK et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185:2600-10.
66. van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol 249:395-408.
67. Wooldridge L, Laugel B, Ekeruche J et al CD8 controls T cell cross-reactivity. J Immunol 2010; 185:4625-32.
68. Arstila T, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human αβ T cell receptor diversity. Science 1999; 286:958-61.
69. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2:417-26.
70. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4+ memory-phenotype T cells are abundant in unexposed adults. Immunity 2013; 38:373-83.
71. Wucherpfennig KW, Sethi D. T cell receptor recognition of self and foreign antigens in the induction of autoimmunity. Semin Immunol 2011; 23:84-91.
72. Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr Opin Immunol 2008; 20:575-80.
73. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81.
74. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9.
75. Li Y, Moysey R, Molloy PE et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23:349-54.
76. Kieke MC, Shusta EV, Boder ET, Teyton L, Wittrup KD, Kranz DM. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc Natl Acad Sci USA 96:5651-6.
77. Hawse WF, Champion MM, Joyce MV et al. Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J Immunol 2012; 188:5819-23.
78. Irving M, Zoete V, Hebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287:23068-78.
79. Varela-Rohena A, Molloy PE, Dunn SM et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008; 14:1390-5.
80. Aleksic M, Liddy N, Molloy PE et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 42:3174-9.
81. Cole DK, Pumphrey NJ, Boulter JM et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178:5727-34.
82. Tan MP, Gerry AB, Brewer JE et al. TCR binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol in press 2014.
83. Cameron BJ, Gerry AB, Dukes J et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5:197ra103.
84. Linette GP, Stadtmauer EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 22:863-71.
85. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333-47.
86. Liddy N, Bossi G, Adams KJ et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012; 18:980-7.
87. Sheridan C. Monoclonal T-cell receptor drugs pique pharma's interest. Nat Biotechnol 2013; 31:950-1.
88. Mori L, De Libero G. T cells specific for lipid antigens. Immunol Res 2012; 53:191-9.
89. Birkinshaw RW, Pellicci DG, Cheng TY et al. αβ T cell antigen receptor recognition of CD1a presenting self lipid ligands. Nat Immunol 2015; 16:258-66.
90. Gadola SD, Zaccai NR, Harlos K et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat Immunol 2002; 3:721-6.
91. Roy S, Ly D, Li NS et al. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβ T cells. Proc Natl Acad Sci USA 2014; 11:E4648-57.
92. Luoma AM, Castro CD, Mayassi T et al. Crystal structure of Vδ1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells. Immunity 39:1032-42.
93. Borg NA, Wun KS, Kjer-Nielsen L et al CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007; 448:44-9.
94. Wun KS, Ross F, Patel O et al. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex. J Biol Chem 2012; 287:39139-48.
95. Patel O, Kjer-Nielsen L, Le Nours J et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun 2013; 4:2142.
96. Adams EJ, Chien YH, Garcia KC. Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science 2005; 308:227-31.
97. Patel O, Pellicci DG, Gras S et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2007; 13:857-63.
98. Scharf L, Li NS, Hawk AJ et al. The 2.5 Å structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 2010; 33:853-62.
99. Lepore M, de Lalla C, Gundimeda SR et al. A novel self-lipid antigen targets human T cells against CD1c(+) leukemias. J Exp Med 2014; 211:1363-77.
100. Kjer-Nielsen L, Patel O, Corbett AJ et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012; 491:717-23.
101. Reantragoon R, Kjer-Nielsen L, Patel O et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J Exp Med 2012; 209:761-74.
102. McWilliam HE, Birkinshaw RW, Villadangos JA, McCluskey J, Rossjohn J. MR1 presentation of vitamin B-based metabolite ligands. Curr Opin Immunol 2015; 34C:28-34.
103. Eckle SB, Birkinshaw RW, Kostenko L et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med 2014; 211:1585-600.
104. Corbett AJ, Eckle SB, Birkinshaw RW et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 2014; 509:361-5.
105. Cowan JE, Jenkinson WE, Anderson . The thymus medulla fosters generation of natural Treg cells, invariant γδ T Cells and invariant NKT cells: what we learn from intrathymic migration. Eur J Immunol 2015; 45:652-60.
106. Sandstrom A, Scharf L, McRae G, Hawk AJ, Meredith SC, Adams EJ. γδ T cell receptors recognize the non-classical major histocompatibility complex (MHC) molecule T22 via conserved anchor residues in a MHC peptide-like fashion. J Biol Chem 2012; 287:6035-43
107. Willcox CR, Pitard V, Netzer S et al. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13:872-9.
108. Uldrich AP, Le Nours J, Pellicci DG et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol 2013; 14:1137-45.
109. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8.
110. Morita CT, Beckman EM, Bukowski JF et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 1995; 3:495-507.
111. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995; 375:155-8.
112. Vavassori S, Kumar A, Wan GS et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013; 14:908-16.
113. Sandstrom A, Peigné CM, Léger A et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40:490-500.
114. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279:1737-40.
115. Chen H, He X, Wang Z et al. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy. J Biol Chem 2008; 283:12528-37.
116. Dai Y, Chen H, Mo C, Cui L, He W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity. J Biol Chem 2012; 287:16812-9.
117. Mo C, Dai Y, Kang N, Cui L, He W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J Biol Chem 2012; 287:19242-54.
118. Lu J, Das M, Kanji S et al. Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells. Biochim Biophys Acta 2014; 1842:1071-9.
119. Xu B, Pizarro JC, Holmes MA et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci USA 2011; 108:2414-9.
120. Bruder J, Siewert K, Obermeier B et al. Target specificity of an autoreactive pathogenic human γδ-T cell receptor in myositis. J Biol Chem 2012; 287:20986-95.
121. Aydintug MK, Zhang L, Wang C et al. γδ T cells recognize the insulin B:9-23 peptide antigen when it is dimerized through thiol oxidation. Mol Immunol 2014; 60:116-28.
122. Paul S, Shilpi, Lal G. Role of gamma-delta (γδ) T cells in autoimmunity. J Leukoc Biol 2014; 97:259-71.